FUNCTION OF LATENT TRANSFORMING GROWTH FACTOR-β BINDING PROTEIN-2 (LTBP-2) IN ELASTINOGENESIS AND MODULATION OF GROWTH FACTOR STORAGE, EXPRESSION AND ACTIVITY IN NORMAL AND FIBROTIC TISSUES

Mohamed Arshad Mohamed Sideek

Discipline of Anatomy and Pathology
School of Medicine
The University of Adelaide

April 2016

A thesis submitted in fulfilment of the requirement for the Degree of Doctor of Philosophy in Medicine and Surgery
Table of Contents

Summary ......................................................................................................................... 8
Declaration ...................................................................................................................... 10
Acknowledgements ........................................................................................................ 11
Publication Arising During PhD Candidature ................................................................. 12
Scientific Communications ............................................................................................ 13
Awards and Achievements During Candidature ............................................................. 15
Abbreviations ................................................................................................................ 16

CHAPTER 1: The Role of LTBP-2 in Elastinogenesis and Fibrotic Diseases ............... 19
  1.1 The extracellular matrix (ECM) and its components ............................................ 19
  1.2 Collagens ................................................................................................................ 21
  1.3 Proteoglycans ......................................................................................................... 23
    1.3.1 Heparin/Heparan sulphate proteoglycans ......................................................... 24
  1.4 Glycoprotein .......................................................................................................... 26
  1.5 Elastic fibres ........................................................................................................... 28
    1.5.1 Elastin ............................................................................................................... 28
    1.5.2 Fibrillin-microfibrils ......................................................................................... 30
  1.6 Fibulins .................................................................................................................. 32
    1.6.1 Fibulin-5 .......................................................................................................... 34
  1.7 Fibrotic diseases ..................................................................................................... 37
  1.8 Growth factors ....................................................................................................... 39
    1.8.1 Transforming growth factor – beta (TGF-β) ................................................... 39
    1.8.2 Fibroblast growth factor -2 (FGF-2) ................................................................. 42
  1.9 Latent TGF-β binding proteins (LTBPs) ............................................................... 44
    1.9.1 LTBP-2 ............................................................................................................ 45
  1.10 Aims of the present study .................................................................................... 50
    1.10.1 Specific aims .................................................................................................. 50
    1.10.2 Hypotheses .................................................................................................... 50
  1.11 References ............................................................................................................ 51

CHAPTER 2: LTBP-2 competes with tropoelastin for binding to fibulin-5 and heparin, and is a negative modulator of elastinogenesis ............................................................. 76
  2.1 Abstract .................................................................................................................. 80
  2.2 Introduction ............................................................................................................ 81
2.3 Experimental procedures ........................................................................................................... 83
2.3.1 Materials .................................................................................................................................83
2.3.2 Molecular binding assays .......................................................................................................83
2.3.3 Confocal microscopy ..............................................................................................................84
2.4 Results and discussion ................................................................................................................86
2.4.1 LTBP-2 and tropoelastin have similar binding affinities for fibulin-5 .............................. 86
2.4.2 LTBP-2 can completely block the interaction of tropoelastin with fibulin-5 ............... 86
2.4.3 Heparin shows only minor inhibition of fibulin-5 interaction with tropoelastin and LTBP-2 ............................................................................................................................... 87
2.4.4 LTBP-2 substantially inhibits the interaction of tropoelastin with heparin ............... 87
2.4.5 Co-localization of LTBP-2 with fibrillin-1, fibulin-5 and heparan sulfate proteoglycans in fibroblast matrix ........................................................................................................ 88
2.4.6 Exogenous LTBP-2 blocks elastinogenesis by cultured chondrocytes ....................... 88
2.5 Acknowledgments ......................................................................................................................91
2.6 References .................................................................................................................................91
2.7 Figures .................................................................................................................................... 96
Figure 2.1 LTBP-2 and tropoelastin bind fibulin-5 with similar affinities ............................. 96
Figure 2.2 Inhibition of the fibulin-5- tropoelastin interaction by LTBP-2 and its N-terminal fragment (LTBP-2 NT(H)) ........................................................... 98
Figure 2.3 Heparin shows minor but specific inhibition of LTBP-2 interaction with fibulin-5 ................................................................................................................................. 100
Figure 2.4 LTBP-2 inhibits the interaction of tropoelastin with heparin in a dose-dependent manner. .......................................................................................................................... 102
Figure 2.5 Confocal co-localisation of LTBP-2 with fibulin-5, fibrillin-1, fibronectin and heparan sulfate proteoglycans in fibroblast matrix ......................................................... 104
Figure 2.6 Exogenous LTBP-2 inhibits elastinogenesis by ear cartilage chondrocytes in culture ................................................................. 107
Figure 2.7 LTBP-2 and elastinogenesis ......................................................................................... 108
2.8 Mini-research paper: LTBP-2 inhibits elastin and fibrillin assembly in matrix of fetal bovine ear cartilage chondrocytes ................................................................. 110
2.8.1 Introduction ............................................................................................................................111
2.8.2 Method ..................................................................................................................................111
2.8.3 Results and Discussion .........................................................................................................112
2.8.4 References .............................................................................................................................116
CHAPTER 3: LTBP-2 has a single high-affinity binding site for FGF-2 and blocks FGF-2-induced cell proliferation .......................................................................................................................... 119

3.1 Abstract .................................................................................................................................. 124

3.2 Introduction ............................................................................................................................. 125

3.3 Materials and Methods ............................................................................................................ 127
  3.3.1 Recombinant protein production and purification .............................................................. 127
  3.3.2 Solid Phase Binding Assays ............................................................................................... 128
  3.3.3 Cell proliferation assay ...................................................................................................... 129
  3.3.4 Detection and quantitation of FGFR1 activation ................................................................. 129
  3.3.5 Immunohistochemistry ..................................................................................................... 130

3.4 Results and Discussion ............................................................................................................ 131
  3.4.1 FGF-2 has a strong affinity for LTBP-2 ............................................................................. 131
  3.4.2 FGF-2 binding is confined to a small central region of the LTBP-2 molecule .... 132
  3.4.3 The FGF-2 binding site is close to a heparin-binding region of LTBP-2 ......................... 132
  3.4.4 LTBP-2 blocks FGF-2-induced cell proliferation.............................................................. 133
  3.4.5 LTBP-2 and FGF-2 show similar distributions in fibrotic skin ..................................... 133

3.5 References .............................................................................................................................. 137

3.6 Figures ..................................................................................................................................... 142
  Figure 3.1 Recombinant LTBP-2 fragments .......................................................... 142
  Figure 3.2 LTBP-2 specifically binds FGF-2 but not VEGF, BMP-4, BMP-7 or TGF-beta ..... 143
  Figure 3.3 LTBP-2 interacts strongly with FGF-2 ................................................................. 144
  Figure 3.4 FGF-2 has a single binding domain in the central region of LTBP-2 ................. 145
  Figure 3.5 The FGF-2 binding site is close to the central heparin binding site on LTBP-2 .... 147
  Figure 3.6 LTBP-2 blocks FGF-2-induced cell proliferation .................................................. 148
  Figure 3.7 LTBP-2 and fibrillin-1 colocalize in fibrotic skin .................................................... 150
  Figure 3.8 LTBP-2 and FGF-2 co-localize in keloid tissue ..................................................... 151
  Figure 3.9 Quantitation of LTBP-2 and FGF-2 in normal skin and keloid. ......................... 152

CHAPTER 4: Co-localization of LTBP-2 with FGF-2 in fibrotic human keloid and hypertrophic scar ................................................................................................................................. 153

4.1 Abstract .................................................................................................................................. 158

4.2 Introduction ............................................................................................................................. 159

4.3 Materials and Methods ............................................................................................................ 162
4.3.1 Human tissue samples ........................................................................................................ 162
4.3.2 Antibodies .......................................................................................................................... 162
4.3.3 Immunohistochemistry ........................................................................................................ 162
4.3.4 Quantitative Polymerase Chain Reaction ............................................................................ 164
4.3.5 Statistical analysis ............................................................................................................... 165

4.4 Results .................................................................................................................................. 166

4.4.1 LTBP-2 and FGF-2 do not co-localize in fibroblast cell culture ........................................... 166
4.4.2 LTBP-2 and FGF-2 show extensive co-localizations in fibrotic skin lesions ...................... 166
4.4.3 LTBP-2 shows similar distribution with elastin and fibrillin-1 in fibrotic skin .................. 167
4.4.4 Both LTBP-2 and FGF-2 mRNA expression levels are greatly elevated in hypertrophic scar ............................................................ 168

4.5 Discussion .............................................................................................................................. 169

4.6 References ............................................................................................................................ 173

4.7 Figures .................................................................................................................................. 179

Figure 4.1 Immunofluorescence staining for LTBP-2 and FGF-2 in human foreskin fibroblast (HFF) cultures .................................................................................................................. 179
Figure 4.2 LTBP-2 and FGF-2 co-localize in fibrotic skin lesions .............................................. 180
Figure 4.3 Quantitative immunofluorescence analysis of LTBP-2 and FGF-2 in normal skin, mature scar, hypertrophic scar and keloid tissue ............................................................. 182
Figure 4.4 LTBP-2 co-localizes with fibrillin-1 and elastin in fibrotic skin .................................. 183
Figure 4.5 The expression levels of mRNA for LTBP-2, FGF-2 and TGF-β in fibrotic skin tissues ......................................................................................................................... 184

4.8 Supplementary figures ........................................................................................................ 185

Figure 4.6 Specificity of LTBP-2 and FGF-2 antibodies ............................................................. 185
Figure 4.7 Specificity of secondary antibodies and laser channels ............................................ 186

CHAPTER 5: LTBP-2 stimulates the expression of TGF-β in human fibroblasts via Akt & p38 MAPK signalling pathways .......................................................................................... 187

5.1 Abstract ................................................................................................................................. 192

5.2 Introduction ............................................................................................................................ 193

5.3 Materials and Methods ........................................................................................................ 196

5.3.1 Reagents ........................................................................................................................... 196
5.3.2 Expression and purification of recombinant LTBP-2 and fragments .................................. 196
5.3.3 Cell culture and treatment ............................................................................................... 196
5.3.4 Detection and quantitation of TGF-β .............................................................................. 197
5.3.5 Real-time PCR ................................................................. 198
5.3.6 Measurement of signal phosphorylation.................................. 198
5.3.7 Statistical analysis .................................................................. 199
5.4 Results .......................................................................................... 200
5.4.1 Exogenous LTBP-2 stimulates expression and secretion of TGF-β1 in MSU 1.1 fibroblasts ................................................................. 200
5.4.2 LTBP-2 stimulation of TGF-β synthesis and secretion is dose-dependent. .... 201
5.4.3 Time course for LTBP-2 stimulation of TGF-β upregulation .......... 202
5.4.4 A short exposure to exogenous LTBP-2 is sufficient to stimulate TGF-β upregulation ................................................................. 202
5.4.5 The TGF-β stimulating activity maps to a central region of LTBP-2 consisting of an eight -cys motif flanked by pairs of EGF-like repeats. .................................................. 203
5.4.6 Induction of Akt and p38 phosphorylation by LTBP-2 .................... 204
5.4.7 LTBP-2 stimulates the expression of TGF-β via Akt and p38 MAPK signalling pathways .................................................................. 205
5.4.8 Blocking of integrin αVβ3 receptors partially attenuates TGF-β production by LTBP-2 ................................................................. 205
5.5 Discussion .................................................................................... 207
5.6 References ................................................................................... 213

Figure 5.1 Exogenous LTBP-2 increases TGF-β in conditioned medium which is independent of extracellular matrix .................................................. 220
Figure 5.2 LTBP-2 upregulates TGF-β expression in MSU 1.1 cells ............ 221
Figure 5.3 LTBP-2 upregulates TGF-β in a dose-dependent manner ............ 222
Figure 5.4 Time course for LTBP-2 stimulation of TGF-β production ........ 223
Figure 5.5 A short incubation of MSU 1.1 cells with LTBP-2 is sufficient to upregulate TGF-β expression and secretion. ......................................... 224
Figure 5.6 A central region of LTBP-2 consisting of an 8-cys motif flanked by pairs of EGF-like repeats (fragment LTBP-2C F3) contains the stimulatory activity. .......... 225
Figure 5.7 Exogenous LTBP-2 stimulates phosphorylation of AKT and p38 MAPK in human fibroblasts ................................................................. 226
Figure 5.8 LTBP-2 stimulation of TGF-β upregulation involves Akt and p38 MAPK signalling pathways ................................................................. 227
Figure 5.9 Blocking of integrin αVβ3 receptors partially attenuates TGF-β production induced by LTBP-2 ................................................................. 228
Figure 5.10. Schematic representation of possible signalling pathways involved in the production of TGF-β1 by LTBP-2 ................................................................. 229
CHAPTER 6: Discussion

6.1 LTBP-2 plays an important role in elastinogenesis and elastic fibre assembly ............................................. 230
6.2 Role of LTBP-2 in the regulation of growth factor activities ................................................................. 233
6.3 Co-localization of LTBP-2 and FGF-2 in fibrotic human tissues .............................................................. 234
6.4 LTBP-2 stimulates the expression and secretion of TGF-β ................................................................. 236
6.5 The domain organization of the human LTBP-2 protein ........................................................................ 243
6.6 References .............................................................................................................................................. 245

CHAPTER 7: Conclusions and Future Directions .......................................................................................... 258

7.1 Conclusion .............................................................................................................................................. 258
7.2 Future directions .................................................................................................................................... 258
Summary

LTBP-2 is tightly associated with fibrillin microfibrils and elastic fibres in a range of tissues mainly in the lung, heart, skeletal muscle, placenta, liver and the aorta. LTBP-2 belongs to the fibrillin-LTBP superfamily of extracellular matrix proteins. Unlike other LTBP's, LTBP-2 does not covalently bind TGF-beta and its molecular function remains unclear. LTBP-2 complexes with fibulin-5, an elastin-chaperone protein critical for normal elastic fibre assembly, and it has been suggested that LTBP-2 may preferentially direct fibulin-5-elastin globules onto fibrillin-1 (rather than fibrillin-2) microfibrils during elastinogenesis. However, we have now shown that LTBP-2 inhibits rather than enhances the interaction of tropoelastin with fibulin-5 in vitro. In addition LTBP-2 inhibited elastic fibre assembly in ear cartilage chondrocyte cultures largely at the stage of elastin deposition onto the fibrillin microfibril scaffold. In parallel experiments, LTBP-2 was shown to significantly inhibit the binding of heparin to tropoelastin suggesting LTBP-2 may compete with tropoelastin for binding to certain cell surface HSPGs and contribute to controlling the release of elastin microassemblies from the cell surface. Confocal microscopy showed strong co-distribution of LTBP-2 with fibulin-5 and fibrillin-1 and partial co-distribution with HSPGs, perlecan and syndecan-4 in fibroblast matrix. Thus it is evident that LTBP-2 is a negative modulator of elastinogenesis and that LTBP-2 levels may regulate the rate and extent of elastinogenesis in some tissues.

A recent study has linked LTBP-2 gene mutations to recessive form of Weill-Marchesani syndrome which is characterised by short stature, thick fibrotic skin and ectopia lentis. Since fibrillin-1 mutations can also cause this syndrome it is now clear that LTBP-2 is linked to fibrillin biology, growth factor regulation and fibrosis. To investigate growth factor binding to LTBP-2, our laboratory screened a number of cytokines involved in the pathogenesis of fibrotic disorders and identified a very strong specific interaction of FGF-2. The activity was confined to a central region of the LTBP-2 consisting of 6 EGF-like repeats, suggesting a single binding sequence. The finding presented in this thesis found that 5-fold molar excess LTBP-2 can completely block FGF-2 stimulation of fibroblast proliferation via its receptor. In addition increased levels and extensive co-localisation of LTBP-2 and FGF-2 were observed and quantitated in human hypertrophic scars and keloids. Furthermore, qPCR confirmed consistent elevation of LTBP-2 and FGF-2 expression in samples of these fibrotic tissues. The results
support the concept that increased LTBP-2 expression in fibrotic disorders may increase FGF-2 binding and reduce FGF-2 activity, inhibiting normal repair processes.

Previously we have shown that LTBP-2 competes with LTBP-1 for binding to fibrillin in vitro, suggesting that LTBP-2 may modulate TGF-β storage and activation. In experiments designed to measure displacement of TGF-β complexes from fibrillin microfibrils, our laboratory discovered addition of LTBP-2, or a small bioactive fragment LTBP-2C F3 to MSU 1.1 skin fibroblasts resulted in a large increase in TGF-β levels in culture medium. However the increase in TGF-β the medium was cycloheximide sensitive indicating elevated cellular expression and secretion of TGF-β rather than release of matrix-stored TGF-β. Exogenous LTBP-2 or fragment F3 significantly increased levels of latent TGF-β in the medium after 9h peaking at 15h. The signalling mechanism appears to involve the PI3K/Akt and p38 MAPK pathways, as incubation of cells with LTBP-2 (10µg/ml) elevated Akt 1/2/3 Ser473 and P38 D-8 phosphorylation and inhibition of each pathway completely blocked the synthesis of TGF-β. Investigation of the cell surface receptor for the bioactive fragment of LTBP-2 was less informative. Inhibitory antibody to β1 integrins did not affect the TGF-β upregulation but it was partially inhibited by an antibody to the integrin αVβ3 receptor, suggesting it may be involved in LTBP-2-cell interaction(s) resulting in elevated TGF-β expression.

In conclusion, these findings are consistent with LTBP-2 having novel regulatory functions in elastinogenesis, growth factor modulation and fibrosis which may lead to novel therapy development for fibrotic diseases and tissue repair.
Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due references has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University’s digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Beyond this, I do not wish to place any restriction on access to this thesis.

........................................

(Mohamed Arshad Mohamed Sideek)

1154273 The University of Adelaide

Date: 15/04/2016
Acknowledgements

I am very grateful to a lot of people for their support throughout my Ph.D journey and the production of this thesis. The highest gratitude to my primary supervisor, Dr. Mark Gibson for his constant guidance and encouragement. Thank you for being patience and understanding, and for standing by my side when times get hard. Thank you for teaching me that every mistake is just a learning experience. I am forever indebted to the best supervision over the last four years. I really appreciate it from the bottom of my heart. I would like to thank my co-supervisor, Prof. Allison Cowin, and his research team especially Dr. Zlatko Kopecki, for the opportunity to work in their reputable laboratory. I thank the fantastic members of the Gibson’s lab, Mahroo Parsi, Clementine Menz, and Josh Smith for their help and advice throughout my Ph.D work.

I wholeheartedly thank the greatest gift I have ever had, my mother, Fazila Begum (Amma) for her warm hugs, pleasing smiles and encouraging words, and for all the countless times she has been there for me. To my wonderful dad, Mohamed Sideek (Atta), I could not begin to list all the ways his love has made all the difference in my life. Amma and Atta, I am blessed to have both of you in my life, I love you so much! To my one and only brother and sister, Jamal Mohideen and Nur Saminah, I cannot thank you enough for their amazing support, unconditional love and care. I could not imagine my life without you.

My deepest appreciation belongs to my wife and my soul mate, Noor Shafiqa, who has always been my strength. I do not know how I can ever thank you for being such a loving and caring person. Thank you to other family members, Abdul Hadi (grandfather), Mumtaj Begum (grandmother), Haji Mohamed (father-in-law), Fathimunnisa (mother-in-law), Mohamed Zahirudin (brother-in-law), Thilsath Yasmine (sister-in-law), Imthiyaz (brother), Rosmah akka (sister), Mohamed Hussain (uncle), Jalifah Nachiya (aunty), Ruknudin mama (uncle), Sajeetha mami (aunty) and Dato’ Haji Mohamed Mustafa (uncle). Without your persistent love and dedication over the past years, none of this would have been possible.

Special thanks to Iqbal Jamaludin and Azuwan Musa, who have been an awesome friends and colleagues. Thank you for always being a good listener and making me laugh when I had almost forgotten how to do so.
CHAPTER 2
LTBP-2 competes with tropoelastin for binding to fibulin-5 and heparin, and is a negative modulator of elastinogenesis

Mohamed A. Sideek, Clementine Menz, Mahroo K. Parsi, Mark A. Gibson

*Matrix Biology* 34 (2014) 114-123 (*Impact factor: 5.074*)

LTBP-2 inhibits elastin and fibrillin assembly in matrix of fetal bovine ear cartilage chondrocytes

Mohamed A. Sideek and Mark A. Gibson

(manuscript in preparation)

CHAPTER 3
LTBP-2 has a single high-affinity binding site for FGF-2 and blocks FGF-2-induced cell proliferation

Clementine Menz, Mahroo K. Parsi, Julian R.J. Adams, Mohamed A. Sideek, Zlatko Kopecki, Allison J. Cowin, Mark A. Gibson

*PLOS ONE* 10(8): e013557 (*Impact factor: 3.234*)

CHAPTER 4
Co-localization of LTBP-2 with FGF-2 in fibrotic human keloid and hypertrophic scar

Mohamed A. Sideek, Abdulrahman Teia, Zlatko Kopecki, Allison J. Cowin, Mark A. Gibson

*Journal of Molecular Histology* (*Impact factor: 1.815*)

CHAPTER 5
LTBP-2 stimulates the expression of TGF-β via Akt & p38 MAPK signalling pathway in human fibroblast

Mohamed A. Sideek, Josh Smith, Clementine Menz, Julian R.J. Adams, Allison J. Cowin, Mark A. Gibson

*Matrix Biology* (*Impact factor: 5.074*) (manuscript in preparation)
Scientific Communications

INTERNATIONAL:

2011
The Elastin and Elastic Fibers Gordon Research Conference, University of New England, Biddeford, ME, United States (oral and poster)

NATIONAL AND LOCAL:

2015
Australian Society of Medical Research (ASMR) South Australia Annual Scientific Meeting, National Wine Centre, Adelaide, Australia (poster)

2014
Matrix Biology Society of Australia and New Zealand (MBSANZ) 38th Annual Scientific Meeting, Queenscliff, Victoria, Australia (oral and poster)
Florey International Postgraduate Research Conference, Faculty of Health Sciences (FHS) Postgraduate Research Conference 2014, The University of Adelaide, Adelaide, Australia (poster)
Australian Society of Medical Research (ASMR) South Australia Annual Scientific Meeting, Adelaide Convention Center, Adelaide, Australia (poster)

2013
Matrix Biology Society of Australia and New Zealand (MBSANZ) 37th Annual Scientific Meeting, McCracken Country Club, South Australia, Australia (poster)
Faculty of Health Sciences (FHS) Postgraduate Research Conference 2013, Adelaide, Australia (poster)
Australian Society of Medical Research (ASMR) South Australia Annual Scientific Meeting, Adelaide Convention Center, Adelaide, Australia (poster)

1st Malaysian Postgraduate Student Symposium of South Australia 2013, Adelaide, Australia (oral and poster)

2012

Matrix Biology Society of Australia and New Zealand (MBSANZ) 36th Annual Scientific Meeting, Mantra Legends, Gold Coast, Queensland, Australia (poster)

Postgraduate Research Expo, Faculty of Health Science, University of Adelaide, The National Wine Centre, Adelaide, South Australia, Australia (poster)

Australian Society of Medical Research (ASMR) South Australia Annual Scientific Meeting, Adelaide Convention Center, Adelaide, Australia (poster)

School of Medical Sciences, The University of Adelaide. PhD Introductory Seminar (oral)
Awards and Achievements During Candidature

2014

Shortlisted for the Dennis Lowther Award at Matrix Biology Society of Australia and New Zealand 38th Annual Scientific Meeting, Queenscliff, Victoria, Australia.

School of Medical Sciences Postgraduate Travel Award (National Conference Attendance), Faculty of Health Sciences (FHS), The University of Adelaide, Australia.

2013

Shortlisted for the Dennis Lowther Award at Matrix Biology Society of Australia and New Zealand 37th Annual Scientific Meeting, Victor Harbour, South Australia, Australia.

Academic and Character Excellence Award 2013 (Anugerah Kecemerlangan Akademik dan Sahsiah (AKASIA)). Australian-Malaysian Muslim Solidarity of South Australia (ISMA SA), South Australia, Australia.

2012

Shortlisted for the Dennis Lowther Award at Matrix Biology Society of Australia and New Zealand 36th Annual Scientific Meeting, Mantra Legends, Gold Coast, Queensland, Australia.

IIUM Scholarship (Full), Kulliyyah of Allied Health Sciences, International Islamic University Malaysia (IIUM), Pahang, Malaysia.

SLAB/SLAI (PhD) Scholarship (Full), Ministry of Education (MoE), Malaysia.
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCIP-</td>
<td>5-bromo-4-chloro-3-indolylphosphate toluidine salt</td>
</tr>
<tr>
<td>BMP-</td>
<td>bone morphogenetic protein</td>
</tr>
<tr>
<td>BSA-</td>
<td>bovine serum albumin</td>
</tr>
<tr>
<td>C-</td>
<td>carboxy-terminus</td>
</tr>
<tr>
<td>C-6-S-</td>
<td>chondroitin-6-sulphate</td>
</tr>
<tr>
<td>Ca(^{2+})-</td>
<td>calcium ions</td>
</tr>
<tr>
<td>CaCl(_2)-</td>
<td>calcium chloride</td>
</tr>
<tr>
<td>cbEGF-</td>
<td>calcium binding epidermal growth factor</td>
</tr>
<tr>
<td>cDNA-</td>
<td>complementary deoxyribonucleic acid</td>
</tr>
<tr>
<td>CHX-</td>
<td>cycloheximide</td>
</tr>
<tr>
<td>CS-</td>
<td>chondroitin sulphate</td>
</tr>
<tr>
<td>DAPI-</td>
<td>4′,6-Diamidino-2-phenylindole dihydrochloride</td>
</tr>
<tr>
<td>ddH(_2)O-</td>
<td>double distilled water</td>
</tr>
<tr>
<td>DMEM-</td>
<td>Dulbecco’s Modification of Eagles Medium</td>
</tr>
<tr>
<td>DMSO-</td>
<td>dimethyl sulphoxide</td>
</tr>
<tr>
<td>DNA-</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DTT-</td>
<td>dithiothreitol</td>
</tr>
<tr>
<td>ECM-</td>
<td>extracellular matrix</td>
</tr>
<tr>
<td>EDTA-</td>
<td>ethylene diamine tetraacetic acid</td>
</tr>
<tr>
<td>EGF-</td>
<td>epidermal growth factor</td>
</tr>
<tr>
<td>ELISA-</td>
<td>enzyme-linked immuno-sorbent assay</td>
</tr>
<tr>
<td>EMLIN-</td>
<td>elastinmicrofibril interface located protein</td>
</tr>
<tr>
<td>FCS-</td>
<td>foetal calf serum</td>
</tr>
<tr>
<td>FGF-2</td>
<td>fibroblast growth factor -2</td>
</tr>
<tr>
<td>FGFRs</td>
<td>FGF receptors</td>
</tr>
<tr>
<td>FITC-</td>
<td>fluorescein isothiocyanate</td>
</tr>
<tr>
<td>GAG-</td>
<td>glycosaminoglycan</td>
</tr>
<tr>
<td>GuHCL-</td>
<td>guanidine hydrochloride</td>
</tr>
<tr>
<td>HAC-</td>
<td>heparin-albumin conjugates</td>
</tr>
<tr>
<td>HEK-</td>
<td>human embryo kidney</td>
</tr>
<tr>
<td>HFF-</td>
<td>human foreskin fibroblasts</td>
</tr>
<tr>
<td>his(_6)-</td>
<td>6-histidine</td>
</tr>
<tr>
<td>HS-</td>
<td>heparan sulphate</td>
</tr>
<tr>
<td>HSPGs-</td>
<td>heparan sulphate proteoglycans</td>
</tr>
<tr>
<td>HTS-</td>
<td>hypertrophic scar</td>
</tr>
<tr>
<td>IgG-</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IL-</td>
<td>interleukin</td>
</tr>
<tr>
<td>K(_d)-</td>
<td>dissociation constant</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>kDa-</td>
<td>kiloDalton</td>
</tr>
<tr>
<td>LAP-</td>
<td>latency-associated protein</td>
</tr>
<tr>
<td>LLC-</td>
<td>large latent complex</td>
</tr>
<tr>
<td>LTBP-</td>
<td>latent transforming growth factor-β binding protein</td>
</tr>
<tr>
<td>LTBP-2C (H)-</td>
<td>LTBP-2 C-terminal</td>
</tr>
<tr>
<td>LTBP-2NT (H-)</td>
<td>LTBP-2 N-terminal</td>
</tr>
<tr>
<td>M-</td>
<td>molar</td>
</tr>
<tr>
<td>MAGP-</td>
<td>microfibrillar-associated glycoprotein</td>
</tr>
<tr>
<td>MAPK-</td>
<td>mitogen-activated protein kinases</td>
</tr>
<tr>
<td>MFS-</td>
<td>Marfan syndrome</td>
</tr>
<tr>
<td>min-</td>
<td>minutes</td>
</tr>
<tr>
<td>mM-</td>
<td>millimolar</td>
</tr>
<tr>
<td>MMP-</td>
<td>matrix metalloprotease</td>
</tr>
<tr>
<td>mRNA-</td>
<td>messenger RNA</td>
</tr>
<tr>
<td>N-</td>
<td>amino-terminus</td>
</tr>
<tr>
<td>NaCl-</td>
<td>sodium chloride</td>
</tr>
<tr>
<td>NBCS-</td>
<td>new born calf serum</td>
</tr>
<tr>
<td>NBT-</td>
<td>nitro-blue tetrazolium chloride</td>
</tr>
<tr>
<td>NEAA-</td>
<td>non-essential amino acids</td>
</tr>
<tr>
<td>ng-</td>
<td>nanogram</td>
</tr>
<tr>
<td>Ni-</td>
<td>nickel</td>
</tr>
<tr>
<td>NRS-</td>
<td>normal rabbit serum</td>
</tr>
<tr>
<td>PBS-</td>
<td>phosphate-buffered saline</td>
</tr>
<tr>
<td>PCR-</td>
<td>polymerase chain reactions</td>
</tr>
<tr>
<td>PG-</td>
<td>proteoglycan</td>
</tr>
<tr>
<td>PVDF-</td>
<td>polyvinylidene difluoride</td>
</tr>
<tr>
<td>r-</td>
<td>recombinant</td>
</tr>
<tr>
<td>RGD-</td>
<td>arginine-glycine-aspartic acid motif</td>
</tr>
<tr>
<td>RNA-</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>RT-</td>
<td>room temperature</td>
</tr>
<tr>
<td>SD-</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SDS-PAGE-</td>
<td>sodium sulphate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>SLC-</td>
<td>small latent complex</td>
</tr>
<tr>
<td>SMA-</td>
<td>smooth muscle actin</td>
</tr>
<tr>
<td>SMC-</td>
<td>smooth muscle cell</td>
</tr>
<tr>
<td>TBS-</td>
<td>tris buffered saline</td>
</tr>
<tr>
<td>TGF-β-</td>
<td>transforming growth factor-β</td>
</tr>
<tr>
<td>TIMP-</td>
<td>tissue inhibitor of metalloproteinases</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>TMB-</td>
<td>tetramethylbenzidine</td>
</tr>
<tr>
<td>v or vol-</td>
<td>volume</td>
</tr>
<tr>
<td>w-</td>
<td>weight</td>
</tr>
<tr>
<td>WMS-</td>
<td>Weill-Marchesani syndrome</td>
</tr>
<tr>
<td>α-</td>
<td>alpha</td>
</tr>
<tr>
<td>αVβ3-</td>
<td>alpha V beta 3</td>
</tr>
<tr>
<td>αVβ5-</td>
<td>alpha V beta 5</td>
</tr>
<tr>
<td>β-</td>
<td>beta</td>
</tr>
<tr>
<td>μl-</td>
<td>microliter</td>
</tr>
<tr>
<td>Δ</td>
<td>delta</td>
</tr>
<tr>
<td>8-cys-</td>
<td>8-cysteine containing motif</td>
</tr>
</tbody>
</table>